U.S. Peripheral Vascular Angiography Contrast Media Market Size, Share & Trends Analysis Report By Modality (Ultrasound, Magnetic Resonance Imaging (MRI), CT/X-ray), By Product (Iodinated, Microbubble, Gadolinium-Based), By End Use, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The U.S. peripheral vascular angiography contrast media market size was estimated at USD 232.91 million in 2024 and is projected to grow at a CAGR of 6.29% from 2025 to 2030. The rising prevalence of Peripheral Vascular Diseases (PVDs) in the U.S. is a significant driver of the peripheral vascular imaging contrast media market. Increased need for advanced diagnostic and therapeutic tools to manage these conditions effectively. According to the Heart Disease and Stroke Statistics by the American Heart Association 2023, prevalence of Peripheral Artery Disease (PAD) estimates indicate 7 to 12 million affected individuals in the U.S.

The growing burden of peripheral artery disease is anticipated to boost the U.S. peripheral vascular angiography contrast media industry growth over the forecast period. Peripheral vascular angiography is conducted to diagnose peripheral artery disease. According to an article published by the Trustees of the University of Pennsylvania in June 2024, an estimated 21 million Americans already live with peripheral artery disease (PAD), and this number is anticipated to grow to 24 million by 2030.

The growing prevalence of the aging population in countries such as the U.S. and Japan is expected to drive market growth. Older individuals are more prone to developing peripheral vascular or peripheral artery diseases. According to data from the Population Reference Bureau published in January 2024, the number of people aged 65 and older in the U.S. is projected to increase by 47%, from 58 million in 2022 to 82 million by 2050. The proportion of the population aged 65 and above is anticipated to rise from 17% to 23%. Aging is a significant risk factor for vascular and chronic diseases. As the geriatric population grows, there will be an increased prevalence of chronic conditions such as cardiovascular diseases and other lifestyle-related disorders, further elevating the risk of peripheral artery diseases.

The increasing prevalence of lifestyle-related disorders, such as diabetes, obesity, smoking, and hypertension, is a major driver of the peripheral vascular angiography contrast media market. These conditions are strongly associated with a higher risk of vascular diseases, including peripheral artery disease, atherosclerosis, and other circulatory disorders. As the global incidence of these conditions rises, the demand for diagnostic imaging procedures, including angiography with contrast media, has also grown. Peripheral vascular angiography procedures, which rely on contrast agents to produce clear and precise images of blood vessels, play a critical role in the early diagnosis of these conditions, enabling timely interventions that can enhance patient outcomes.

Market Concentration & Characteristics

The market growth stage is moderate, and the pace of its growth is accelerating. The market is characterized by acquisitions, partnerships, technological advancements, and increasing regulatory approval for novel product launches.

The degree of innovation in the peripheral vascular angiography contrast media market influences the development of new products and the enhancement of existing ones. Innovative contrast agents are being developed to improve visualization, reduce adverse reactions, and enhance patient safety. Advances in technology, including targeted delivery systems and the use of artificial intelligence for image analysis, are also shaping the market. Furthermore, ongoing research aims to create contrast media with better tolerability and lower toxicity. These innovations improve diagnostic capabilities and contribute to more effective treatment planning and outcomes for patients with peripheral vascular diseases.

Companies in the peripheral vascular angiography contrast media market pursue acquisitions to expand their product portfolios. For instance, companies acquire smaller firms with innovative contrast media products, including microbubble-based agents or non-iodinated alternatives, to diversify their offerings and meet the growing demand for safer, more effective contrast agents. Such strategic acquisitions allow larger firms to enter new market segments or strengthen their presence in specific imaging modalities.

Regulatory agencies such as the U.S. FDA, European Medicines Agency, and other regional bodies set stringent safety and efficacy standards for contrast media products. Before being introduced into the market, contrast agents must undergo strict clinical trials to demonstrate their safety profile, effectiveness, and compatibility with various imaging modalities. These regulatory requirements ensure that only high-quality, reliable products are available to healthcare providers.

There is a growing trend towards developing non-iodinated contrast agents, such as microbubbles, which are safer for patients with kidney issues or allergies than traditional iodinated agents. These alternatives are expected to gain market share as they provide safer and more accessible options for peripheral vascular angiography. Manufacturers are improving iodinated contrast media formulations to reduce side effects such as nephrotoxicity and allergic reactions. Newer formulations with better safety profiles, faster clearance from the body, and improved imaging capabilities are being introduced to meet the growing demand for effective yet safer contrast agents.

Companies seek to strengthen their presence in high-demand areas. Urban regions with advanced healthcare infrastructure offer significant opportunities, while rural and underserved areas are being targeted for growth through partnerships with local distributors and healthcare providers.

Product Insights

The CT/X-ray segment dominated the market in 2024 and is expected to register a significant CAGR from 2025 to 2030. CT angiography is a medical imaging technique that combines a CT scan with injecting a special dye called contrast material. This dye helps to visualize blood vessels and tissues better during the scan. A CT scan is an X-ray that uses a computer to generate cross-sectional images of the body. The contrast material is crucial for CT angiography as it enhances the visibility of the examined structures. CT angiography utilizes minimal radiation, minimizing the associated risks. While there's always a slight theoretical risk with any radiation exposure, the benefits of accurate diagnosis typically outweigh these minimal concerns. Importantly, no radiation remains within the body after a CT scan. The rising prevalence of Congenital Heart Diseases (CHDs) significantly increases the demand for CT angiography. Accurate diagnosis and effective management of CHDs necessitate precise imaging techniques, and CT angiography has emerged as an invaluable tool in this context. For instance, as per a report by the CDC, in October 2024, in the U.S., nearly 1% of babies are born with heart defects, amounting to an estimated 40,000 newborns annually.

Ultrasound imaging is a non-invasive, safe, and cost-effective technique that provides real-time imaging, making it ideal for assessing peripheral vascular conditions. As a radiation-free alternative to X-ray and CT scans, ultrasound is preferred, particularly in patients requiring frequent imaging or sensitivity to ionizing radiation. Further, advancements in ultrasound technology, such as higher resolution and better imaging capabilities, enhance its utility in vascular imaging. The growing demand for non-iodinated contrast agents and the development of microbubble-based contrast agents is driving ultrasound’s adoption in peripheral vascular angiography. With its ability to provide detailed and dynamic images of blood flow and vessel structure, ultrasound is expected to contribute to its fastest growth in the market.

Modality Insights

Iodinated contrast media dominated the peripheral vascular angiography contrast media market due to their high efficacy in enhancing the visibility of blood vessels in imaging modalities such as X-ray, CT, and angiography. These agents improve the contrast and clarity of vascular structures, enabling accurate diagnosis and treatment planning. Their well-established safety profile and consistent and predictable results have made them a trusted choice among healthcare professionals. In addition, iodinated contrast media are versatile, compatible with various imaging techniques, and offer fast action with predictable outcomes, making them ideal for emergency and routine diagnostic scenarios. With a strong market presence from leading companies like Bayer and GE HealthCare, iodinated contrast agents dominate the market, driven by their proven effectiveness and wide usage.

The microbubble modality segment is expected to grow fastest in the peripheral vascular angiography contrast media market. Microbubbles offer a minimally invasive, patient-friendly alternative to traditional iodinated contrast agents, particularly in cases where patients are sensitive to iodinated agents or require repeated imaging. They enhance the resolution and sensitivity of ultrasound imaging, allowing for superior visualization of blood vessels and improving the detection of peripheral vascular diseases. Advancements in microbubble technology, such as more stable and longer-lasting formulations, are further expanding their clinical use. In addition, the increasing demand for non-iodinated alternatives, driven by concerns over nephrotoxicity and allergic reactions associated with iodinated agents, contributes to the growing adoption of microbubbles. With their expanding applications in diagnostics, microbubbles are poised to become a significant player in the peripheral vascular angiography contrast media market.

End Use Insights

The hospital end use segment dominated the market in 2024. The hospital segment of the peripheral vascular angiography contrast media market is a key driver of growth, as hospitals are the primary healthcare setting for performing vascular imaging procedures. These procedures, which use contrast media to visualize blood vessels and diagnose vascular diseases, are crucial in treating conditions such as peripheral artery disease (PAD) and other vascular abnormalities. In this segment, the demand for PVA contrast media is influenced by factors such as increasing patient volumes, advancements in imaging technology, and the rising prevalence of vascular diseases.

The diagnostic imaging centers segment is anticipated to grow significantly over the forecast period, driven by rising demand for advanced diagnostic services and non-invasive imaging technologies. These centers, which specialize in procedures such as angiography, are adopting PVA contrast media due to their effectiveness in improving the visualization of blood vessels. This enhancement is crucial for diagnosing vascular conditions such as peripheral artery disease and vascular blockages, further fueling the market expansion in this segment.

Key U.S. Peripheral Vascular Angiography Contrast Media Company Insights:

The key players operating in the U.S. market are adopting product approval to increase the reach of their products in the market and improve the availability of their products in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Recent Developments

• In December 2024, at the 2024 Radiological Society of North America annual meeting, Bayer showcased advancements in its radiology portfolio, highlighting progress in AI, medical imaging, and contrast agents. Bayer presented Phase III data on its investigational low-dose macrocyclic gadolinium-based contrast agent, which enables reduced dosing while maintaining diagnostic efficacy. The research, honored with the Kuo York Chynn Neuroradiology Research Award, focuses on its pharmacokinetics, dose selection, and imaging potential for CNS lesions and MR angiography.

• In October 2024, GE HealthCare announced the successful completion of its Phase I clinical trial for a macrocyclic manganese-based MRI contrast agent. The study demonstrated that the agent was well tolerated, with no serious adverse events, dose-limiting toxicities, or clinically relevant findings reported.

• In July 2024, Bracco and Verasonics, Inc. announced a strategic partnership aimed at enhancing research in medical imaging. This collaboration will merge Verasonics' Vantage NXT Research Ultrasound Systems with Bracco's contrast agents to investigate enhanced imaging performance across a range of research applications. The agreement also entails joint marketing initiatives, including online content and webinars, to present the outcomes of their research efforts.

• In April 2024, the Bracco Group announced that it will launch its direct autonomous presence in the Japanese market starting April 2024. The newly formed Bracco Japan will gradually replace Bracco Eisai, the joint venture that was established in 1990 and renewed twice.

U.S. Peripheral Vascular Angiography Contrast Media Market Report Scope

U.S. Peripheral Vascular Angiography Contrast Media Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. peripheral vascular angiography contrast media market report based on product, modality, and end use:

• Product Outlook (Revenue, USD Million; 2018 - 2030)

  • CT/X-ray

  • Magnetic Resonance Imaging

  • Ultrasound

• Modality Outlook (Revenue, USD Million; 2018 - 2030)

  • Iodinated Contrast Media

  • Gadolinium-based Contrast Media

  • Microbubble

• End Use Outlook (Revenue, USD Million; 2018 - 2030)

  • Hospitals

  • Diagnostic Imaging Centers

  • Research Institutes

  • Others